Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1440-1449

  Kennedy, Richard D ^a   Chen, Clark C ^a   Stuckert, Patricia ^a   Archila, Elyse M ^a   De La Vega, Michelle A ^a   Moreau, Lisa A ^a   Shimamura, Akiko ^a   D'Andrea, Alan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; KU 55933; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG INHIBITION; ENZYME ACTIVATION; FANCONI ANEMIA; FIBROBLAST; GENOMIC INSTABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR CELL;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELLS, CULTURED; DNA DAMAGE; DNA-BINDING PROTEINS; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP C PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP G PROTEIN; HELA CELLS; HUMANS; MICE; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 34248184445     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31245     Document Type: Article

References (54)

1. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
2. Lengauer, C., Kinzler, K.W., and Vogelstein, B. 1998. Genetic instabilities in human cancers. Nature. 396:643-649.
3. Kaelin, W.G., Jr. 1999. Choosing anticancer drug targets in the postgenomic era. J. Clin. Invest. 104:1503-1506.
4. Marnett, L.J., Riggins, J.N., and West, J.D. 2003. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J. Clin. Invest. 111:583-593. doi:10.1172/JCI200318022.
5. Kennedy, R.D., and D'Andrea, A.D. 2006. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J. Clin. Oncol. 24:3799-3808.
6. D'Andrea, A.D., and Grompe, M. 2003. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer. 3:23-34.
7. Zou, L., and Elledge, S.J. 2003. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 300:1542-1548.
8. Andreassen, P.R., D'Andrea, A.D., and Taniguchi, T. 2004. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 18:1958-1963.
9. Wang, X., Andreassen, P.R., and D'Andrea, A.D. 2004. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol. Cell. Biol. 24:5850-5862.
10. Garcia-Higuera, I., et al. 2001. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell. 7:249-262.
11. Taniguchi, T., et al. 2002. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood. 100:2414- 2420.
12. Nakanishi, K., et al. 2002. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat. Cell Biol. 4:913-920.
13. Hussain, S., et al. 2004. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum. Mol. Genet. 13:1241-1248.
14. Niedzwiedz, W., et al. 2004. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell. 15:607-620.
15. King, M.C., Marks, J.H., and Mandell, J.B. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302:643-646.
16. Hahn, S.A., et al. 2003. BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl. Cancer Inst. 95:214-221.
17. Cantor, S., et al. 2004. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc. Natl. Acad. Sci. U. S. A. 101:2357-2362.
18. Seal, S., et al. 2006. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38:1239-1241.
19. Couch, F.J., et al. 2005. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 65:383-386.
20. van der Heijden, M.S., et al. 2004. Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am. J. Pathol. 165:651-657.
21. Condie, A., et al. 2002. Analysis of the Fanconi anaemia complementation group A gene in acute myeloid leukaemia. Leuk. Lymphoma. 43:1849-1853.
22. Tischkowitz, M.D., et al. 2004. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia. 18:420-425.
23. Xie, Y., et al. 2000. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br. J. Haematol. 111:1057-1064.
24. Pejovic, T., et al. 2006. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. Cancer Res. 66:9017-9025.
25. Dhillon, V.S., Shahid, M., and Husain, S.A. 2004. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol. Cancer. 3:33.
26. Narayan, G., et al. 2004. Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res. 64:2994-2997.
27. Marsit, C.J., et al. 2004. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 23:1000-1004.
28. Farmer, H., et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917-921.
29. Bryant, H.E., et al. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913-917.
30. Garcia-Higuera, I., Kuang, Y., Denham, J., and D'Andrea, A.D. 2000. The Fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. Blood. 96:3224-3230.
31. McCabe, N., et al. 2006. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66:8109-8115.
32. Shiloh, Y. 2003. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer. 3:155-168.
33. Ziv, Y., et al. 1997. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene. 15:159-167.
34. Bakkenist, C.J., and Kastan, M.B. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:499-506.
35. Singh, N.P., McCoy, M.T., Tice, R.R., and Schneider, E.L. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175:184-191.
36. Hickson, I., et al. 2004. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64:9152-9159.
37. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods. 184:39-51.
38. Kaelin, W.G., Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer. 5:689-698.
39. Lord, C.J., Garrett, M.D., and Ashworth, A. 2006. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res. 12:4463-4468.
40. Sobeck, A., et al. 2006. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol. Cell. Biol. 26:425-437.
41. Kennedy, R.D., and D'Andrea, A.D. 2005. The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev. 19:2925-2940.
42. Akkari, Y.M., et al. 2001. The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol. Genet. Metab. 74:403-412.
43. Sarkaria, J.N., et al. 1998. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58:4375-4382.
44. Taniguchi, T., et al. 2002. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 109:459-472.
45. Riballo, E., et al. 2004. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol. Cell. 16:715-724.
46. Morrison, C., et al. 2000. The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J. 19:463-471.
47. Naf, D., Kupfer, G.M., Suliman, A., Lambert, K., and D'Andrea, A.D. 1998. Functional activity of the Fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol. Cell. Biol. 18:5952-5960.
48. van der Heijden, M.S., et al. 2005. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin. Cancer Res. 11:7508-7515.
49. Taniguchi, T., and D'Andrea, A.D. 2002. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. Blood. 100:2457-2462.
50. Yang, Y., et al. 2001. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood. 98:3435-3440.
51. Borghesani, P.R., et al. 2000. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc. Natl. Acad. Sci. U. S. A. 97:3336-3341.
52. Wilson, J.B., et al. 2001. The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. Carcinogenesis. 22:1939-1946.
53. Yamashita, T., Barber, D.L., Zhu, Y., Wu, N., and D'Andrea, A.D. 1994. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc. Natl. Acad. Sci. U. S. A. 91:6712-6716.
54. Garcia-Higuera, I., Kuang, Y., Naf, D., Wasik, J., and D'Andrea, A.D. 1999. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol. Cell. Biol. 19:4866-4873.